Skip to main content
. 2022 Sep 9;72(4):827–840. doi: 10.1007/s00262-022-03283-5

Fig. 5.

Fig. 5

Proposed metabolic rewiring (with lipid consumption instead of only glutamine and glucose feeding). This is the first clinical evidence that this metabolic adaptation is used by colorectal cancer cells, after avelumab and ADC therapy, to boost oxidative stress and contribute to cancer progression. Oxidative stress is compensated in IMMETCOLS cluster 3 tumors with anti-oxidative pathways such as pentose-phosphate pathway